[1] Kim SK, Lim HK, Kim YH, et al. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics. 2003;23(1):107–121.
[2] Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with fol- low-up multiphase helical CT. Radiology. 2001;221(2):447–454.
[3] Passera K, Selvaggi S, Scaramuzza D, et al. Radiofrequency abla- tion of liver tumors: quantitative assessment of tumor coverage through CT image processing. BMC Med Imaging. 2013;13(1):3.
[4] Sakakibara M, Ohkawa K, Katayama K, et al. Three-dimensional registration of images obtained before and after radiofrequency ablation of hepatocellular carcinoma to assess treatment adequacy. AJR Am J Roentgenol. 2014;202(5):487–495.
[5] Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clin- ical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasonud Med Biol. 2013;39(2):187–210.
[6] Westwood M, Joore M, Grutters J, et al. Contrast enhanced ultra- sound using SonoVueVR (sulphur hexafluoride microbubbles) com- pared with contrast-enhanced computed tomography and contrastenhanced magnetic resonance imaging for the character-isation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17(16):1–243.
[7] Wiesinger I, Wiggermann P, Zausig N, et al. Percutaneous treat- ment of malignant liver lesions: evaluation of success using con- trast- enhanced ultrasound (CEUS) and perfusion software. Ultraschall Med. 2018;39(4):440–447.
[8] Wen YL, Kudo M, Zheng RQ, et al. Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast- enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol. 2003; 181(1):57–63.
[9] Kisaka Y, Hirooka M, Kumagi T, et al. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radio- frequency ablation. Liver Int. 2006;26(10):1241–1247.
[10] Numata K, Fukuda H, Morimoto M, et al. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubu-tane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma. Eur J Radiol. 2012;81(10):2746–2753.
[11] Hao Y, Numata K, Ishii T, et al. Rate of local tumor progression following radiofrequency ablation of pathologically early hepato- cellular carcinoma. World J Gastroenterol. 2017;23(17):3111–3121.
[12] Nishigori S, Numata K, Irie K, et al. Fusion imaging with contrast- enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepa- tocellular carcinomas with iso-echoic or unclear margins on con-ventional ultrasonography. J Med Ultrasonics. 2018;45(3):405–415.
[13] Makino Y, Imai Y, Igura T, et al. Feasibility of extracted-overlay fusion imaging for intraoperative treatment evaluation of radio- frequency ablation for hepatocellular carcinoma. Liver Cancer. 2016;5(4):269–279.
[14] Ma QP, Xu EJ, Zeng QJ, et al. Intraprocedural computed tomog- raphy/magnetic resonance-contrast-enhanced ultrasound fusion imaging improved thermal ablation effect of hepatocellular car- cinoma: comparison with conventional ultrasound. Hepatol Res. 2019;49(7):799–809.
[15] Xu EJ, Lv SM, Li K, et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/ contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia. 2018;34(6):870–876.
[16] Kudo M, Matsui O, Izumi N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcin- oma: 2014 update by the liver cancer study group of Japan. Liver Cancer. 2014;3(3–4):458–468.
[17] Sugimori K, Numata K, Okada M, et al. Central vascular structures as a characteristic finding of regenerative nodules using hepato- biliary phase gadolinium ethoxybenzyl diethylenetriaminepenta- acetic acid-enhanced MRI and arterial dominant phase contrast- enhanced US. J Med Ultrasonics. 2017;44(1):89–100.
[18] Numata K. Advances in ultrasound systems for hepatic lesions in Japan. J Med Ultrasonics. 2015;42(3):297–301.
[19] Numata K, Fukuda H, Miwa H, et al. Contrast-enhanced ultrason- ography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol. 2014; 83(1):95–102.
[20] Numata K, Fukuda H, Nihonmatsu H, et al. Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver dis- ease. Abdom Imaging. 2015;40(7):2372–2383.
[21] Ishii T, Numata K, Hao Y, et al. Evaluation of hepatocellular carcin- oma tumor vascularity using contrast-enhanced ultrasonography as a predictor for local recurrence following radiofrequency abla- tion. Eur J Radiol. 2017;89:234–241.
[22] Kunishi Y, Numata K, Morimoto M, et al. Efficacy of fusion imag- ing combining sonography and hepatobiliary phase MRI with Gd- EOB-DTPA to detect small hepatocellular carcinoma. AJR Am J Roentgenol. 2012;198(1):106–114.
[23] Nishikawa H, Osaki Y, Iguchi E, et al. Radiofrequency ablation for hepatocellular carcinoma:the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol. 2013;48(8):951–965.
[24] Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991. p. 1–611.
[25] Seo J, Koizumi N, Funamoto T, et al. Visual serving for a US- guided therapeutic HIFU system by coagulated lesion tracking: a phantom study. Int J Med Robotics Comput Assist Surg. 2011; 7(2):237–247.
[26] Cha DI, Lee MW, Song KD, et al. A prospective comparison between auto-registration and manual registration of real-time ultrasound with MR images for percutaneous ablation or biopsy of hepatic lesions. Abdom Radiol. 2017;42(6):1799–1808.
[27] Huang Q, Zeng Z. A review on real-time 3d ultrasound imaging technology. Biomed Res Int. 2017;2017:1–20.